Evidence map›Paper›PMID 36207326›Full record

ArticleScientific reports2022

Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals.

Mariliis Jaago, Annika Rähni, Nadežda Pupina, Arno Pihlak, Helle Sadam, Jürgen Tuvikene, Annela Avarlaid, Anu Planken, Margus Planken, Liina Haring and 11 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Low-doseFrontiers in immunology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 4 countries.

Mariliis Jaago *Protobios LLC, Tallinn, Estonia.
Annika Rähni *Protobios LLC, Tallinn, Estonia.
Nadežda PupinaProtobios LLC, Tallinn, Estonia.
Arno PihlakProtobios LLC, Tallinn, Estonia.
Helle SadamProtobios LLC, Tallinn, Estonia.
Jürgen TuvikeneProtobios LLC, Tallinn, Estonia.
Annela AvarlaidDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia.
Anu PlankenNorth Estonia Medical Centre Foundation, Tallinn, Estonia.
Margus PlankenNorth Estonia Medical Centre Foundation, Tallinn, Estonia.
Liina HaringInstitute of Clinical Medicine, Psychiatry Clinic of Tartu University Hospital, University of Tartu, Tartu, Estonia.
Eero VasarDepartment of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Miljana BaćevićDental Biomaterial Research Unit (d-BRU), Faculty of Medicine, University of Liege, Liege, Belgium.
France LambertDepartment of Periodontology and Oral Surgery, Faculty of Medicine, University of Liege, Liege, Belgium.
Eija KalsoDepartment of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital, Helsinki, Finland.
Pirkko PussinenOral and Maxillofacial Diseases, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Pentti J TienariTranslational Immunology Research Program, Department of Neurology, Neurocenter, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Antti VaheriDepartment of Virology, Medicum, University of Helsinki, Helsinki, Finland.
Dan LindholmDepartment of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Tõnis TimmuskProtobios LLC, Tallinn, Estonia.
Amir M GhaemmaghamiImmunology and Immuno-Bioengineering Group, School of Life Science, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom.
Kaia PalmProtobios LLC, Tallinn, Estonia. kaia@protobios.com.
Protobios (Estonia) · EEHelsinki University Hospital · FINorth Estonia Medical Centre · EETallinn University of Technology · EEUniversity of Helsinki · FIUniversity of Liège · BEMinerva Foundation · FITartu University Hospital · EEUniversity of Nottingham · GBUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunity to previously encountered viruses can alter response to unrelated pathogens. We reasoned that similar mechanism may also involve SARS-CoV-2 and thereby affect the specificity and the quality of the immune response against the virus. Here, we employed high-throughput next generation phage display method to explore the link between antibody immune response to previously encountered antigens and spike (S) glycoprotein. By profiling the antibody response in COVID-19 naïve individuals with a diverse clinical history (including cardiovascular, neurological, or oncological diseases), we identified 15 highly antigenic epitopes on spike protein that showed cross-reactivity with antigens of seasonal, persistent, latent or chronic infections from common human viruses. We observed varying degrees of cross-reactivity of different viral antigens with S in an epitope-specific manner. The data show that pre-existing SARS-CoV-2 S1 and S2 cross-reactive serum antibody is readily detectable in pre-pandemic cohort. In the severe COVID-19 cases, we found differential antibody response to the 15 defined antigenic and cross-reactive epitopes on spike. We also noted that despite the high mutation rates of Omicron (B.1.1.529) variants of SARS-CoV-2, some of the epitopes overlapped with the described mutations. Finally, we propose that the resolved epitopes on spike if targeted by re-called antibody response from SARS-CoV-2 infections or vaccinations can function in chronically ill COVID-19 naïve/unvaccinated individuals as immunogenic targets to boost antibodies augmenting the chronic conditions. Understanding the relationships between prior antigen exposure at the antibody epitope level and the immune response to subsequent infections with viruses from a different strain is paramount to guiding strategies to exit the COVID-19 pandemic.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralAntibody FormationAntigens, ViralChronic DiseaseEpitopesHumansPandemicsSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralAntigens, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID36207326
PMCPMC9540097
OpenAlexW4303415485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.